Evidence map›Paper›PMID 37305172›Full record

ArticleAmerican heart journal plus : cardiology research and practice2023

Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis.

Frederick Berro Rivera, Vincent Anthony S Tang, Deogracias Villa De Luna, Edgar V Lerma, Krishnaswami Vijayaraghavan, Amir Kazory, Nilay S Shah, Annabelle Santos Volgman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American heart journal plus : cardiology research and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 2 countries.

Frederick Berro RiveraDepartment of Medicine, Lincoln Medical Center, Bronx, NY, USA.
Vincent Anthony S TangDepartment of Medicine, University of the Philippines - Philippine General Hospital, Metro Manila, Philippines.
Deogracias Villa De LunaDepartment of Internal Medicine, Danbury Hospital, Danbury, CT, USA.
Edgar V LermaSection of Nephrology, University of Illinois at Chicago College of Medicine/Advocate Christ Medical Center Oak Lawn, IL, USA.
Krishnaswami VijayaraghavanUniversity of Arizona, AZ, USA.
Amir KazoryDivision of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, FL, USA.
Nilay S ShahDepartment of Medicine (Cardiology), Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Annabelle Santos VolgmanDivision of Cardiology, Rush University Medical Center, Chicago, IL, USA.
Danbury Hospital · USLincoln Medical Center · USNorthwestern University · USPhilippine General Hospital · PHRush University Medical Center · USUniversity of Arizona · USUniversity of Florida · USUniversity of Illinois Chicago · US

Funding

MASALA-2G: Multi-level Assessment of the South Asian Life-course of Atherosclerosis (2nd Generation Offspring Study)K23HL157766 · NORTHWESTERN UNIVERSITY · 2025 to 2025
$226k
NHLBI NIH HHS K23 HL157766
6 · The paper itself

Abstract

Background: In patients with heart failure (HF), randomized controlled trials (RCTs) of sodium-glucose transporter-2 inhibitors (SGLT-2is) have proven to be effective in decreasing the primary composite outcome of cardiovascular death and hospitalizations for HF. A recently published meta-analysis showed that the use of SGLT-2is among women with diabetes resulted in less reduction in primary composite outcomes compared with men. This study aims to explore potential sex differences in primary composite outcomes among patients with HF treated with SGLT-2is. Methods: We systematically searched the medical database from 2017 to 2022 and retrieved all the RCTs using SGLT-2is with specified cardiovascular outcomes. We used the PRISMA (Preferred Reporting Items for a Review and Meta-analysis) method to screen for eligibility. We evaluated the quality of studies using the Cochrane Risk of Bias tool. We pooled the hazard ratio (HR) of the primary composite outcomes in both sexes, performed a meta-analysis, and calculated the odds ratio (OR) of the primary composite outcomes based on sex. Results: We included 5 RCTs with a total number of 21,947 patients. Of these, 7837 (35.7 %) were females. Primary composite outcomes were significantly lower in males and females taking SGLT-2is compared to placebo (males - HR 0.77; 95 % CI 0.72 to 0.84; Conclusion: SGLT-2is reduce the risk of primary composite outcomes in patients with HF, regardless of sex; however, the benefits were less pronounced in women. Further research needs to be done to better explain these observed differences in outcomes.

Indexed as

CardiorenalCardiovascular outcomesHeart failureSex differencesSGLT-2 inhibitors

Identifiers

PMID37305172
PMCPMC10256233
OpenAlexW4319659284

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.